• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Over $42 Million Bet On This Biotechnology Stock? 4 Penny Stocks Insiders are Buying

    7/14/22 8:15:56 AM ET
    $CAMP
    $CXDO
    $ETTX
    $SEAC
    Telecommunications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CAMP alert in real time by email

    US producer prices likely to rise 0.8% on the month in June to match the previous month’s growth. Investors, meanwhile, focused on some notable insider trades.

    When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3

    SeaChange International

    • The Trade: SeaChange International, Inc. (NASDAQ:SEAC) 10% owner Karen Singer acquired a total of 424,942 shares at an average price of $0.54. To acquire these shares, it cost around $230.22 thousand.
    • What’s Happening: SeaChange, and Triller, last month, announced they mutually agreed to terminate their proposed merger.
    • What SeaChange International Does: SeaChange International Inc is a provider of multiscreen video solutions for television service providers, telecommunications companies, satellite operators, and media companies.

    Entasis Therapeutics

    • The Trade: Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) 10% owner Innoviva Strategic Opportunities LLC acquired a total of 19,270,476 shares at an average price of $2.20. The insider spent around $42.4 million to buy those shares.
    • What’s Happening: Entasis Therapeutics, last month, highlighted presentation of data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference.
    • What Entasis Therapeutics Does: Entasis Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria.

    Bitcoin Breaches $20,000, Here's The Top Crypto Movers For Thursday

    Don’t forget to check out our premarket coverage here .

    CalAmp

    • The Trade: CalAmp Corp. (NASDAQ:CAMP) Director Wes Cummins acquired a total of 374,207 shares at an average price of $4.13. To acquire these shares, it cost around $1.55 million.
    • What’s Happening: CalAmp recently reported worse-than-expected Q1 adjusted EPS and sales results.
    • What CalAmp Does: CalAmp Corp provides wireless communications solutions applications to customers.

    Crexendo

    • The Trade: Crexendo, Inc. (NASDAQ:CXDO) CEO Steven G Mihaylo acquired a total of 10,000 shares at an average price of $2.89. The insider spent $28.9 thousand to buy those shares.
    • What’s Happening: The company’s stock gained 25% over the past month.
    • What Crexendo Does: Crexendo Inc is a provider of cloud communications, UCaaS, call center, collaboration services, and other cloud business services.
    Get the next $CAMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAMP
    $CXDO
    $ETTX
    $SEAC

    CompanyDatePrice TargetRatingAnalyst
    CAMP4 Therapeutics Corporation
    $CAMP
    10/2/2025$7.00Overweight
    Cantor Fitzgerald
    CAMP4 Therapeutics Corporation
    $CAMP
    9/16/2025Overweight → Neutral
    Analyst
    Crexendo Inc.
    $CXDO
    7/1/2025$8.00Buy
    Needham
    CAMP4 Therapeutics Corporation
    $CAMP
    5/27/2025$8.00Outperform
    Wedbush
    Crexendo Inc.
    $CXDO
    4/7/2025$8.00Buy
    Craig Hallum
    Crexendo Inc.
    $CXDO
    1/21/2025$7.00Buy
    D. Boral Capital
    CAMP4 Therapeutics Corporation
    $CAMP
    11/5/2024Outperform
    William Blair
    CAMP4 Therapeutics Corporation
    $CAMP
    11/5/2024$18.00Overweight
    Piper Sandler
    More analyst ratings

    $CAMP
    $CXDO
    $ETTX
    $SEAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CAMP4 Appoints Michael MacLean to its Board of Directors

    CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the appointment of Michael MacLean to the Company's Board of Directors. "Mike brings an exceptional depth of financial and operational expertise built across decades of leadership at some of the most innovative biotechnology companies, and we are thrilled to welcome him to CAMP4's Board," said Josh Mandel-Brehm, Pr

    3/24/26 7:00:00 AM ET
    $CAMP

    CAMP4 to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare ConferenceFormat:Fireside ChatDate and Time:March 9, 2026, 8:40 a.m. ETLocation:Miami, FLWebcast Link:Click Here  Stifel CNS ForumFormat:Corporate PresentationDate and Time:March 17, 2026, 10:00 a.m.

    3/6/26 4:05:00 PM ET
    $CAMP

    CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights

    GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance RNA-based therapeutic discoveries, received $17.5 million upfront and eligible for milestone-based payments in addition to tiered royalties Completed private placement with upfront gross proceeds of $50 million, with potential for up to an additional $50 million of gross proceeds, as well as underwritten offering of common stock of $30 million in gross proceeds, extending cash runway into 2028 CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDA

    3/5/26 4:05:00 PM ET
    $CAMP

    $CAMP
    $CXDO
    $ETTX
    $SEAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on CAMP4 Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $7.00

    10/2/25 8:38:59 AM ET
    $CAMP

    CAMP4 Therapeutics downgraded by Analyst

    Analyst downgraded CAMP4 Therapeutics from Overweight to Neutral

    9/16/25 8:02:50 AM ET
    $CAMP

    Needham initiated coverage on Crexendo with a new price target

    Needham initiated coverage of Crexendo with a rating of Buy and set a new price target of $8.00

    7/1/25 8:17:53 AM ET
    $CXDO
    Telecommunications Equipment
    Telecommunications

    $CAMP
    $CXDO
    $ETTX
    $SEAC
    SEC Filings

    View All

    CAMP4 Therapeutics Corporation filed SEC Form 8-K: Leadership Update

    8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

    3/24/26 7:02:55 AM ET
    $CAMP

    Crexendo Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Crexendo, Inc. (0001075736) (Filer)

    3/6/26 12:33:55 PM ET
    $CXDO
    Telecommunications Equipment
    Telecommunications

    SEC Form S-8 filed by CAMP4 Therapeutics Corporation

    S-8 - Camp4 Therapeutics Corp (0001736730) (Filer)

    3/5/26 4:15:46 PM ET
    $CAMP

    $CAMP
    $CXDO
    $ETTX
    $SEAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Tardiff Daniel

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    4/3/26 4:48:21 PM ET
    $CAMP

    SEC Form 4 filed by Maricich Yuri

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    4/3/26 4:47:38 PM ET
    $CAMP

    SEC Form 4 filed by Gold Kelly

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    4/3/26 4:47:04 PM ET
    $CAMP

    $CAMP
    $CXDO
    $ETTX
    $SEAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner 5am Partners Vi, Llc bought $4,499,999 worth of shares (2,941,176 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/15/25 8:12:20 PM ET
    $CAMP

    Large owner Polaris Management Co. Vii, L.L.C. bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/11/25 4:59:09 PM ET
    $CAMP

    Director Nashat Amir bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/11/25 4:48:30 PM ET
    $CAMP

    $CAMP
    $CXDO
    $ETTX
    $SEAC
    Leadership Updates

    Live Leadership Updates

    View All

    CAMP4 Appoints Michael MacLean to its Board of Directors

    CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the appointment of Michael MacLean to the Company's Board of Directors. "Mike brings an exceptional depth of financial and operational expertise built across decades of leadership at some of the most innovative biotechnology companies, and we are thrilled to welcome him to CAMP4's Board," said Josh Mandel-Brehm, Pr

    3/24/26 7:00:00 AM ET
    $CAMP

    Sequans Appoints Jason W. Cohenour to Board of Directors

    Paris, France--(Newsfile Corp. - June 30, 2025) - Sequans Communications S.A. (NYSE:SQNS), a leading innovator in cellular IoT semiconductor solutions, today announced the appointment of Jason W. Cohenour to its Board of Directors.Mr. Cohenour brings more than 30 years of executive leadership experience across sales, operations, and international mergers and acquisitions. He served as President, CEO, and Director of Sierra Wireless, Inc. (TSX:SW) (NASDAQ:SWIR) from 2005 to 2018, where he led a strategic transformation that created a global leader in the Internet of Things and drove company revenues to nearly USD $800 million. Prior to his CEO role, he held several senior positions at Sierra

    6/30/25 8:00:00 AM ET
    $CAMP
    $LTRX
    $RFIL
    Computer Communications Equipment
    Telecommunications
    Electrical Products
    Technology

    CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

    With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company's Board of Directors. "We are delighted to welcome Drs. William

    3/18/25 8:00:00 AM ET
    $CAMP

    $CAMP
    $CXDO
    $ETTX
    $SEAC
    Financials

    Live finance-specific insights

    View All

    Crexendo Delivers Strong Third Quarter Results

    PHOENIX, AZ / ACCESSWIRE / November 6, 2024 / Crexendo, Inc. (NASDAQ:CXDO), an award-winning software technology company that is a premier provider of cloud communication platform and services, video collaboration and managed IT services tailored to businesses of all sizes, today announced financial results for the third quarter ended September 30, 2024.Financial highlights:Revenue of $15.6 million, up 13% year-over-yearNet income of $0.1 million, or $0.01 per basic common share and $0.00 per diluted common share.Non-GAAP net income of $1.6 million, or $0.06 per basic and diluted common shareFinancial Results for the Third quarter of 2024Total Revenue: Consolidated total revenue for the thir

    11/6/24 4:00:00 PM ET
    $CXDO
    Telecommunications Equipment
    Telecommunications

    Crexendo, Inc. to Issue Third Quarter 2024 Financial Results on November 6, 2024, at 4:30 PM ET

    PHOENIX, AZ / ACCESSWIRE / October 18, 2024 / Crexendo, Inc. (NASDAQ:CXDO) announced it will hold its third quarter 2024 financial results conference call on November 6, 2024, at 4:30 PM ET. Jeff Korn, Chief Executive Officer, Doug Gaylor, President and Chief Operating Officer and Ron Vincent, Chief Financial Officer, will deliver prepared remarks and conduct a question-and-answer session.The dial-in number for domestic participants is 888-506-0062 and 973-528-0011 for international participants and reference participant access code 993699. Please dial in five minutes prior to the beginning of the call at 4:30 PM ET and reference the Crexendo earnings call and access code 993699. A replay of

    10/18/24 9:00:00 AM ET
    $CXDO
    Telecommunications Equipment
    Telecommunications

    Crexendo Delivers Strong Second Quarter Results

    PHOENIX, AZ / ACCESSWIRE / August 6, 2024 / Crexendo, Inc. (NASDAQ:CXDO), an award-winning premier provider of cloud communication platform and services, video collaboration and managed IT services designed to provide enterprise-class cloud solutions to any size business, today announced financial results for the second quarter ended June 30, 2024.Financial highlights:Revenue of $14.7 million, up 16% year-over-yearNet income of $0.6 million, up 220% year-over-yearNon-GAAP net income of $2.1 million, up 91% year-over-yearEPS of $0.02 per basic and diluted common share, up 200% year-over-yearNon-GAAP EPS of $0.08 per basic and $0.07 per diluted common share, up 100% and 75%, respectively year-

    8/6/24 4:00:00 PM ET
    $CXDO
    Telecommunications Equipment
    Telecommunications

    $CAMP
    $CXDO
    $ETTX
    $SEAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

    SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 6:49:57 PM ET
    $CAMP

    SEC Form SC 13D filed by CAMP4 Therapeutics Corporation

    SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 5:50:56 PM ET
    $CAMP

    SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

    SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 4:19:08 PM ET
    $CAMP